vs

Side-by-side financial comparison of Guardforce AI Co., Ltd. (GFAI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $18.0M, roughly 1.1× Guardforce AI Co., Ltd.). Guardforce AI Co., Ltd. runs the higher net margin — -76.9% vs -177.4%, a 100.5% gap on every dollar of revenue. On growth, Guardforce AI Co., Ltd. posted the faster year-over-year revenue change (6.3% vs -11.5%).

Guardforce AI Co., Ltd. is a global provider of AI-integrated security solutions. Its core offerings include intelligent surveillance systems, AI-powered access control, autonomous security robots, and smart logistics monitoring services, serving enterprise, retail, financial and public sector clients across Asia, Europe and North America.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

GFAI vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.1× larger
LAB
$19.6M
$18.0M
GFAI
Growing faster (revenue YoY)
GFAI
GFAI
+17.7% gap
GFAI
6.3%
-11.5%
LAB
Higher net margin
GFAI
GFAI
100.5% more per $
GFAI
-76.9%
-177.4%
LAB

Income Statement — Q2 FY2023 vs Q3 FY2025

Metric
GFAI
GFAI
LAB
LAB
Revenue
$18.0M
$19.6M
Net Profit
$-13.8M
$-34.7M
Gross Margin
12.0%
48.5%
Operating Margin
-66.1%
-168.5%
Net Margin
-76.9%
-177.4%
Revenue YoY
6.3%
-11.5%
Net Profit YoY
-118.5%
-28.8%
EPS (diluted)
$-4.35
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GFAI
GFAI
LAB
LAB
Q3 25
$19.6M
Q2 25
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
GFAI
GFAI
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
GFAI
GFAI
LAB
LAB
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
GFAI
GFAI
LAB
LAB
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
GFAI
GFAI
LAB
LAB
Q3 25
-177.4%
Q2 25
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
GFAI
GFAI
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GFAI
GFAI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$24.7M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$25.0M
$399.7M
Total Assets
$64.1M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GFAI
GFAI
LAB
LAB
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
GFAI
GFAI
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
GFAI
GFAI
LAB
LAB
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
GFAI
GFAI
LAB
LAB
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
GFAI
GFAI
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GFAI
GFAI
LAB
LAB
Operating Cash FlowLast quarter
$-1.0M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GFAI
GFAI
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
GFAI
GFAI
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
GFAI
GFAI
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
GFAI
GFAI
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GFAI
GFAI

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons